Lymphatic therapies open the valve in Marfan syndrome.
Y, T. & KM, C. (2026). Lymphatic therapies open the valve in Marfan syndrome.. The Journal of clinical investigation. https://doi.org/10.1172/JCI209169
Y T, KM C. Lymphatic therapies open the valve in Marfan syndrome.. The Journal of clinical investigation. 2026; doi: 10.1172/JCI209169
Y T, KM C. Lymphatic therapies open the valve in Marfan syndrome.[J]. The Journal of clinical investigation. 2026. DOI: 10.1172/JCI209169.
@article{y2026,
author = {Tian Y and Caron KM},
title = {Lymphatic therapies open the valve in Marfan syndrome.},
journal = {The Journal of clinical investigation},
year = {2026},
doi = {10.1172/JCI209169},
note = {PMID: 42544580},
}
TY - JOUR AU - Tian Y AU - Caron KM TI - Lymphatic therapies open the valve in Marfan syndrome. T2 - The Journal of clinical investigation PY - 2026 DO - 10.1172/JCI209169 AN - PMID:42544580 ER -
Myxomatous degeneration of the mitral valve (MDMV) is a common cardiovascular manifestation of Marfan syndrome (MFS), yet the role of lymphatic vessels in the disease progression remains unknown. In this Commentary, we discuss the study by Tan, Kume, and colleagues, which identifies defective lymphangiogenesis as a previously unrecognized driver of MDMV. Their work demonstrates that impaired lymphatic development and drainage promote valve inflammation through reduced ZFP36-mediated antiinflammatory signaling, whereas restoration of lymphatic function or pharmacological activation of ZFP36 with the FDA-approved drug FTY720 ameliorates disease progression. These findings establish lymphatic vessels as critical regulators of mitral valve homeostasis and support exploration of lymphatic-targeted therapeutic opportunities for MFS-associated valvular disease.